Scholarlink

<p>YCANTH<sup>®</sup> (cantharidin) topical solution, 0.7%, hereafter referred to as cantharidin 0.7% topical solution, a vesicant drug-device combination product, is an effective option for molluscum contagiosum in patients aged 2 years and older. Approved in the USA for the treatment of molluscum contagiosum, its single-use applicator device allows for the precise topical application of a standardized formulation of cantharidin 0.7% solution to molluscum contagiosum lesions. In two phase 3 clinical trials, topical application of cantharidin 0.7% solution to molluscum contagiosum lesions once every 21 days as needed (up to a maximum of four applications) resulted in a significantly higher proportion of patients with complete clearance of molluscum contagiosum lesions than vehicle over a period of 84 days. Cantharidin 0.7% topical solution was generally well tolerated. The most common adverse reactions at the application site were vesicles, pruritus, pain, erythema, and scab, which were generally mild or moderate in severity. No serious adverse events related to treatment were reported in clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cantharidin 0.7% topical solution (YCANTH®) in molluscum contagiosum: a profile of its use

  • 期刊论文

  • 发表日期：

    2025年1月11日

查看全文
  • Amy Zhuang-Yan,
  • Hannah A. Blair

摘要

YCANTH® (cantharidin) topical solution, 0.7%, hereafter referred to as cantharidin 0.7% topical solution, a vesicant drug-device combination product, is an effective option for molluscum contagiosum in patients aged 2 years and older. Approved in the USA for the treatment of molluscum contagiosum, its single-use applicator device allows for the precise topical application of a standardized formulation of cantharidin 0.7% solution to molluscum contagiosum lesions. In two phase 3 clinical trials, topical application of cantharidin 0.7% solution to molluscum contagiosum lesions once every 21 days as needed (up to a maximum of four applications) resulted in a significantly higher proportion of patients with complete clearance of molluscum contagiosum lesions than vehicle over a period of 84 days. Cantharidin 0.7% topical solution was generally well tolerated. The most common adverse reactions at the application site were vesicles, pruritus, pain, erythema, and scab, which were generally mild or moderate in severity. No serious adverse events related to treatment were reported in clinical trials.